Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medifast (MED) EBITDA (2016 - 2025)

Historic EBITDA for Medifast (MED) over the last 16 years, with Q4 2025 value amounting to -$7.8 million.

  • Medifast's EBITDA fell 120056.42% to -$7.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$14.2 million, marking a year-over-year decrease of 59364.36%. This contributed to the annual value of -$14.2 million for FY2025, which is 59384.99% down from last year.
  • Medifast's EBITDA amounted to -$7.8 million in Q4 2025, which was down 120056.42% from -$4.1 million recorded in Q3 2025.
  • In the past 5 years, Medifast's EBITDA ranged from a high of $61.4 million in Q2 2021 and a low of -$7.9 million during Q2 2024
  • In the last 5 years, Medifast's EBITDA had a median value of $29.1 million in 2022 and averaged $25.8 million.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 12436.15% in 2021, then plummeted by 120056.42% in 2025.
  • Medifast's EBITDA (Quarter) stood at $46.8 million in 2021, then plummeted by 30.4% to $32.6 million in 2022, then tumbled by 73.39% to $8.7 million in 2023, then plummeted by 91.83% to $709000.0 in 2024, then tumbled by 1200.56% to -$7.8 million in 2025.
  • Its last three reported values are -$7.8 million in Q4 2025, -$4.1 million for Q3 2025, and -$1.1 million during Q2 2025.